Results 11 to 20 of about 71,892 (273)
Patterns of resistance development with integrase inhibitors in HIV
Infection and Drug Resistance, 2011 Raltegravir, the only integrase (IN) inhibitor approved for use in HIV therapy, has recently been licensed. Raltegravir inhibits HIV-1 replication by blocking the IN strand transfer reaction. More than 30 mutations have been associated with resistance to raltegravir and other IN strand transfer inhibitors (INSTIs).
P Cane, Jean L. Mbisa, Martín
openalex +5 more sources
Probing chelation motifs in HIV integrase inhibitors [PDF]
Proceedings of the National Academy of Sciences, 2012 A series of HIV integrase (HIV-1 IN) inhibitors were synthesized to evaluate the role of the metal-binding group (MBG) in this class of metalloenzyme inhibitors.
A. Agrawal +7 more
semanticscholar +4 more sources
Treatment of HIV Infections with HIV Integrase Inhibitors. [PDF]
ACS Med Chem Lett, 2017 Abdel-Magid AF.
europepmc +5 more sources
Prevalence and associated factors of metabolic syndrome among people living with HIV in a medical center of Northern Taiwan [PDF]
Scientific ReportsHIV acquisition has been found to be associated with increased risk of cardiometabolic syndrome in the past. In this study, we attempt to delineate the associated factors of metabolic syndrome among persons living with HIV in a single medical center in ...
Chien-An Tu +13 more
doaj +2 more sources
Raltegravir: first in class HIV integrase inhibitor
Therapeutics and Clinical Risk Management, 2008 Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj +5 more sources
Frequency of Major Transmitted Integrase Resistance in Poland Remains Low Despite Change in Subtype Variability [PDF]
VirusesWith the widespread use of integrase inhibitors and the expanding use of long-acting cabotegravir in both pre-exposure prophylaxis and antiretroviral treatment, molecular surveillance on the transmission of integrase resistance has regained clinical ...
Kaja Mielczak +14 more
doaj +2 more sources
Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. [PDF]
PLoS ONE, 2015 Understanding the HIV integrase protein and mechanisms of resistance to HIV integrase inhibitors is complicated by the lack of a full length HIV integrase crystal structure. Moreover, a lentiviral integrase structure with co-crystallised DNA has not been
Peter K Quashie +4 more
doaj +1 more source
Molecules, 2023 As an important antiviral target, HIV-1 integrase plays a key role in the viral life cycle, and five integrase strand transfer inhibitors (INSTIs) have been approved for the treatment of HIV-1 infections so far.
Yu-Chan Wang +8 more
doaj +1 more source
HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. [PDF]
PLoS ONE, 2011 Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in ...
Geoffrey S Gottlieb +18 more
doaj +1 more source
Retrovirology, 2022 Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human immunodeficiency virus (HIV). There are currently four approved for use in treatment-naïve individuals living with HIV; these include first generation raltegravir ...
Alexa Vyain Zhao +5 more
semanticscholar +1 more source